New York-listed Tower Group's £38.6mn injection into Lloyd's insurer Canopius to finance its proposed acquisition of Omega takes the US insurer one step closer to having an established presence within the Lloyd's market.
New York-listed Tower Group's £38.6mn injection into Lloyd's insurer Canopius to finance its proposed acquisition of Omega takes the US insurer one step closer to having an established presence within the Lloyd's market.